论文信息 - A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. - 字舞流文

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.

H. Kantarjian | G. Garcia-Manero | J. Cortes | S. Verstovsek | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | S. Pierce | N. Pemmaraju | K. Newberry | S. Dellasala